Severe Infections of Soft Tissues (Including Fasciitis and Diabetic Foot Infections)

  • Philippe Bernard
  • Erysipelas and other non-necrotizing derma- hypodermal infections are mainly caused by streptococci, though other bacteria can cause such infections, which often occur in specific circumstances.

  • There is an increasing prevalence of soft-tissue infections (STIs) caused by community-acquired MRSA which are responsible for about half of the cases of cellulitis with purulent exudates in involved geographic areas. Contrary to erysipelas, the best therapeutic option will be an antibiotic that is effective both against streptococci and S. aureus.

  • Treatment of necrotizing fasciitis, a rare, life-threatening infection, primarily affecting the superficial muscular fascia and adjacent hypo-dermis, is surgical excision of all necrotic tissue; it must be considered as an emergency once the diagnosis is suspected.

  • Diagnosis of purulent diabetic foot infections within soft tissues or localized osteomyelitis generally requires imaging investigations. The initial empirical antibacterial regimen may be tailored based on the results of bacteriological cultures.


Septic Arthritis Necrotizing Fasciitis Toxic Shock Syndrome Good Therapeutic Option Streptococcal Toxic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bernard P, Bedane C, Mounier M et al (1995) Bacterial dermo-hypodermatitis in adults. IncIDence and role of streptococcal etiology. Ann Dermatol Venereol 122: 495–500PubMedGoogle Scholar
  2. 2.
    Bisno A, Stevens D (1996) Streptococcal infections of skin and soft tissuesN Engl J Med 334:240–245PubMedCrossRefGoogle Scholar
  3. 3.
    Consensus conference: Management of erysipelas and necrotizing fasciitis (2001) Ann Dermatol Venereol 128:463–482Google Scholar
  4. 4.
    Bernard P, Bedane C, Mounier M et al (1989) Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol 125:779–782PubMedCrossRefGoogle Scholar
  5. 5.
    Leppard BJ, Seal DV, Colman G (1985) The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 112:559–567PubMedCrossRefGoogle Scholar
  6. 6.
    Goettsch WG, Bouwes Bavinck JN, Herings RMC (2006) Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 20:834–839PubMedGoogle Scholar
  7. 7.
    Dupuy A, Benchikhi H, Roujeau JC et al (1999) Risk factors for erysipelas of the leg (cellulitis): case-control study. Br Med J 318:1591–1594Google Scholar
  8. 8.
    Roujeau JC, Paul C et al (2004) Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case control study. Dermatology 209:301–307PubMedCrossRefGoogle Scholar
  9. 9.
    Ronnen M, Suster S, Schewach-Millet et al (1985) Erysipelas: changing faces. Int J Dermatol 24:169–172PubMedGoogle Scholar
  10. 10.
    Crickx B, Chevron F, Sigal-Nahum M et al (1991) Erysipelas: epIDemiological, clinical and therapeutic data (111 cases). Ann Dermatol Venereol 118:11–16PubMedGoogle Scholar
  11. 11.
    Leclerc S, Teixeira A Mahé E et al (2007) Recurrent erysipelas: 47 cases. Dermatology 214:52–57PubMedCrossRefGoogle Scholar
  12. 12.
    Vignes S, Dupuy A (2006) Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibio-therapy: a retrospective cohort study. J Eur Acad Dermatol 20:818–822Google Scholar
  13. 13.
    Coste N, Perceau G, Leone J et al (2004) Osteoarticular complications of erysipelas. J Am Acad Dermatol 50:203–209PubMedCrossRefGoogle Scholar
  14. 14.
    Kopp M, Bernard P, Schmit JL (2001) [Dealing with bacterial hypodermal infection in general practice: an inquiry and a prospective study]. Ann Dermatol Venereol 128: 338–344PubMedGoogle Scholar
  15. 15.
    Musette P, Benichou J, Noblesse I et al (2004) Determinants of severity for superficial cellutitis (erysipelas) of the leg: a retrospective study. Eur J Intern Med 15:446–450PubMedCrossRefGoogle Scholar
  16. 16.
    Jegou J, Hansmann Y, Chalot F et al (2002) Hospitalization criteria for erysipelas: prospective study in 145 cases. Ann Dermatol Venereol 129:375–379PubMedGoogle Scholar
  17. 17.
    Stevens DL, Bisno AL, Chambers HF et al (2005). Practice guIDelines for the management of skin and soft tissue infections. Clin Infect Dis 41:1373–1406PubMedCrossRefGoogle Scholar
  18. 18.
    Jorup-Rönström C, Britton C, Gavlevik A et al (1984) The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 12:390–394PubMedCrossRefGoogle Scholar
  19. 19.
    Bernard P, ChosIDow O, Vaillant L (2002) Oral pristinamy-cin versus standard penicillin regimen to treat erysipelas in adult patients: randomised, non-inferiority, open trial. Br Med J 325:864–866CrossRefGoogle Scholar
  20. 20.
    Estines O, Coste N, Perceau G et al (2003) [Haemorrhagic cellulitis: three cases]. Ann Dermatol Venereol 130:523–526PubMedGoogle Scholar
  21. 21.
    Heng MC, Khoo M, Cooperman A, Fallon-Friedlander S (1994) Haemorragic cellulitis: a syndrome associated with tumour necrosis factor-alpha. Br J Dermatol 130:65–74PubMedCrossRefGoogle Scholar
  22. 22.
    Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674PubMedCrossRefGoogle Scholar
  23. 23.
    Gabillot-Carré M, Roujeau JC (2007) Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis 20:118–123PubMedCrossRefGoogle Scholar
  24. 24.
    Phillips S, MacDougall C, Holdford DA et al (2007) Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus. Ann Pharmacother 41:13–20PubMedGoogle Scholar
  25. 25.
    Hasham S, Matteuci P, Stanley PR et al (2005) Necrotising fasciitis. Br Med J 330:830–833CrossRefGoogle Scholar
  26. 26.
    Liu YM, Chi CY, Ho MW et al (2005) Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect 38:430–435PubMedGoogle Scholar
  27. 27.
    Miller LG, Perdreau-Remington F, Rieg G et al (2005) Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352:1445–1453PubMedCrossRefGoogle Scholar
  28. 28.
    Kaul R, McGeer A, Low DE et al (1997) Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario group A Streptococcal study. Am J Med 103:18–24PubMedCrossRefGoogle Scholar
  29. 29.
    Zerr DM, Alexander ER, Duchin JS et al (1999) A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 103:783–790PubMedCrossRefGoogle Scholar
  30. 30.
    Aronoff DM, Bloch KC (2003) Assessing the relationship between the use of nonsteroIDal anti-inflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 82:225–235CrossRefGoogle Scholar
  31. 31.
    Revelon G, Rhamouni A, Jazaerli X et al (1999) Acute swelling of the limbs: magnetic resonance pictorial review of fascial and muscle signal changes. Eur J Radiol 30:11–21PubMedCrossRefGoogle Scholar
  32. 32.
    Saiag P, LeBreton C, Pavlovic M et al (1994) Magnetic resonance imaging in adults presenting with severe acute infectious cellulitis. Arch Dermatol 130:1150–1158PubMedCrossRefGoogle Scholar
  33. 33.
    Golger A, Ching S, Goldsmith CH et al (2007) Mortality in patients with necrotizing fasciitis. Plast Reconstr Surg 119:1803–1807PubMedCrossRefGoogle Scholar
  34. 34.
    Voros D, Pissiotis C, Antoniou S et al (1993) Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br J Surg. 80:1190–1191PubMedCrossRefGoogle Scholar
  35. 35.
    Société de Pathologie Infectieuse de Langue Française (2007) Short text. Management of diabetic foot infections. Med Mal Infect 37:1–25Google Scholar
  36. 36.
    International Working Group on the Diabetic Foot (2003) International consensus on the diabetic foot [CD-ROM]. In: International Diabetes Foundation; Brussels. http// www.iwgdf.orgGoogle Scholar
  37. 37.
    Lipsky BA, Berendt AR, Embil J, De Lalla F (2004) Diagnosing and treating diabetic foot infections. Diab Metab Res Rev 20:s56–s64CrossRefGoogle Scholar
  38. 38.
    Lavery A, Harkless LB, Felder-Johnsn K, Mundine S (1994) Bacterial pathogens in infected puncture wounds in adults with diabetes. J Foot Ankle Surg 33:91–97PubMedGoogle Scholar
  39. 39.
    El-Tahawy A (2000) Bacteriology of diabetic foot. Saudi Med J 213:44–47Google Scholar
  40. 40.
    Dang CN, Prasad YDM, Boulton AJ, Jude EB (2003) Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diab Med 20: 159–161CrossRefGoogle Scholar
  41. 41.
    Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J (2005) The global burden of diabetic foot disease. Lancet 336:1719–1724CrossRefGoogle Scholar
  42. 42.
    Lavery LA, Armstrong DG, Wunderlich RP et al (2006) Risk factors for foot infections in indivIDuals with diabetes. Diab Care 29:1288–1293CrossRefGoogle Scholar
  43. 43.
    Capriotti G, Chianelli M, Signore A (2006) Nuclear medicine imaging of diabetic foot infection: results of meta-anal-ysis. Nucl Med Commun 27:757–764PubMedCrossRefGoogle Scholar
  44. 44.
    El-Maghraby TA, Moustafa HM, Pauwels EK (2006) Nuclear medicine methods for evaluation of skeletal infection among other diagnostic modalities. Q J Nucl Med Mol Imag 50:167–192Google Scholar
  45. 45.
    Ertrugul MB, Baktiroglu S, Salman S et al (2006) The diagnosis of osteomyelitis of the foot in diabetes: microbiological examination vs. magnetic resonance imaging and labelled leucocyte scanning. Diab Med 23:649–653CrossRefGoogle Scholar
  46. 46.
    Kumar V (2005) Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Q J Nucl Med Mol Imaging 49:325–338PubMedGoogle Scholar
  47. 47.
    Armstrong DG, Lavery LA, Harkless LB (1998) The contribution of depth, infection and ischemia to risk of amputation. Diab Care 21:855–858CrossRefGoogle Scholar
  48. 48.
    Rao N, Lipsky BA (2007) Optimising antimicrobial therapy in diabetic foot infections. Drugs 67:195–214PubMedCrossRefGoogle Scholar
  49. 49.
    Lipsky BA, Sheehan P, Armstrong DG et al (2007) Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. Int Wound J 4:30–38PubMedCrossRefGoogle Scholar
  50. 50.
    Nelson EA, O'Meara S, Golder S et al (2006) Systematic review of antimicrobial treatments for diabetic foot ulcers. Diab Med 23:348–359CrossRefGoogle Scholar
  51. 51.
    Pisky A, Armstrong DG, Citron DM et al (2005) Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trialLancet 366:1695–1703CrossRefGoogle Scholar
  52. 52.
    Cruciani M, Libsky BA, Mengoli C et al (2005) Are granu-locyte colony-stimulating factors beneficial in treating diabetic foot infections? Diab Care 28:454–460CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Philippe Bernard
    • 1
  1. 1.Department of DermatologyRobert Debré HospitalReimscedexFrance

Personalised recommendations